Vaccinex, Inc. (NASDAQ:VCNX) was founded in April 2001 and is headquartered in Rochester, New York, USA. It has 44 full-time employees (7/20/2018). It is a clinical-stage biotechnology company engaged in targeted biotechnology. The discovery and development of therapeutic drugs to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune diseases.
Vaccinex, Inc. (VCNX):
Vaccinex has developed a variety of proprietary platform technologies and is developing candidate products to solve serious diseases or conditions that have a major impact on daily functions, and can be fully resolved through existing therapies. The company uses its proprietary platform technology, including through the cooperation of its academic collaborators, to identify potential candidate products, to continue to expand the company’s internal product line, and to promote strategic development and business cooperation.
Vaccinex is a leader in the field of semaphorin 4D (SEMA4D) biology, and is the only company that uses SEMA4D as a potential treatment for cancer, neurodegenerative diseases and autoimmune diseases. SEMA4D is an extracellular signaling molecule that can regulate the migration of immune and inflammatory cells to sites of injury, cancer or infection.
Vaccinex is using the company’s SEMA4D antibody platform and its extensive knowledge of SEMA4D biology to develop the company’s main product candidate VX15/2503, and the company believes that they utilize a new mechanism of action. Vaccinex focuses on the development of VX15 for the treatment of non-small cell lung cancer (NSCLC), osteosarcoma, melanoma and Huntington’s disease.
In addition to the SEMA4D antibody platform, Vaccinex also has the ActivMAb antibody development platform, a proprietary human antibody discovery platform, based on a new library of full-length human monoclonal antibodies that express a large number of high-affinity, full-length human monoclonal antibodies on the surface of vaccinia (mammalian virus). method.
Vaccinex’s detailed ActivMAb technology provides:
(I) Rapid production of high-affinity, full-length, human monoclonal antibodies synthesized and naturally modified in mammalian cells;
(Ii) Expression and selection of antibodies that can be easily and predictably transformed into mammalian production lines;
(Iii) An innovative and effective method for selecting antibodies against multi-pass membrane proteins, which is an important class of pharmacological targets.
Vaccinex’s product candidate VX5 is developed on the ActivMAb platform and is currently undergoing preclinical development for the treatment of multiple sclerosis (MS) and potentially other autoimmune diseases. The company intends to continue to use its ActivMAb platform to identify other product candidates for its product pipeline development and strategic cooperation.
Vaccinex, Inc. (VCNX) investment:
Vaccinex, Inc. (NASDAQ:VCNX) submitted its IPO prospectus on 7/9/2018, and landed on Nasdaq on August 9, 2018, with an issue price of US$12.00, issuing 3.333 million shares and raising US$40 million. Oppenheimer / BTIG joint underwriting.